Li Jiang, Yang Fan, Li Jian, Huang Zhi-Yong, Cheng Qi, Zhang Er-Lei
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Shihezi University, Shihezi 832000, Xinjiang Uygur Autonomous Regions, China.
World J Gastrointest Surg. 2023 Jan 27;15(1):19-31. doi: 10.4240/wjgs.v15.i1.19.
Hepatocellular carcinoma (HCC) is one of the most lethal tumors in the world. Liver resection (LR) and liver transplantation (LT) are widely considered as radical treatments for early HCC. However, the recurrence rates after curative treatment are still high and overall survival is unsatisfactory. Microvascular invasion (MVI) is considered to be one of the important prognostic factors affecting postoperative recurrence and long-term survival. Unfortunately, whether HCC patients with MVI should receive postoperative adjuvant therapy remains unknown. In this review, we summarize the therapeutic effects of transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine protein kinase inhibitor-based targeted therapy, and immune checkpoint inhibitors in patients with MVI after LR or LT, aiming to provide a reference for the best adjuvant treatment strategy for HCC patients with MVI after LT or LR.
肝细胞癌（HCC）是全球最致命的肿瘤之一。肝切除术（LR）和肝移植（LT）被广泛认为是早期HCC的根治性治疗方法。然而，根治性治疗后的复发率仍然很高，总体生存率也不尽人意。微血管侵犯（MVI）被认为是影响术后复发和长期生存的重要预后因素之一。遗憾的是，MVI的HCC患者是否应接受术后辅助治疗仍不明确。在本综述中，我们总结了经动脉化疗栓塞、肝动脉灌注化疗、基于酪氨酸蛋白激酶抑制剂的靶向治疗以及免疫检查点抑制剂在LR或LT术后MVI患者中的治疗效果，旨在为LT或LR术后MVI的HCC患者最佳辅助治疗策略提供参考。
